• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Treating Attention-Deficit/Hyperactivity Disorder Matters.治疗注意力缺陷多动障碍至关重要。
JAMA. 2024 Mar 12;331(10):831-833. doi: 10.1001/jama.2024.1755.
2
Attention deficit hyperactivity disorder in adults: what the non-specialist needs to know.成人注意力缺陷多动障碍：非专科医生需要了解的内容。
Br J Hosp Med (Lond). 2020 Mar 2;81(3):1-11. doi: 10.12968/hmed.2019.0188. Epub 2020 Mar 16.
3
Attention-deficit/hyperactivity disorder: etiology and pharmacotherapy.注意力缺陷/多动障碍：病因与药物治疗
Arch Iran Med. 2006 Oct;9(4):374-80.
4
Predicting substance use disorder using long-term attention deficit hyperactivity disorder medication records in Truven.利用Truven中的长期注意力缺陷多动障碍用药记录预测物质使用障碍。
Health Informatics J. 2020 Jun;26(2):787-802. doi: 10.1177/1460458219844075. Epub 2019 May 19.
5
A systematic review of reboxetine for treating patients with attention deficit hyperactivity disorder.瑞波西汀治疗注意缺陷多动障碍患者的系统评价
Nord J Psychiatry. 2015 May;69(4):241-8. doi: 10.3109/08039488.2014.972975. Epub 2014 Nov 21.
6
Attention-deficit/hyperactivity disorder: how much responsibility are pediatricians taking?注意力缺陷/多动障碍：儿科医生承担了多少责任？
Pediatrics. 2009 Jan;123(1):248-55. doi: 10.1542/peds.2007-3198.
7
Psychopharmacotherapy of Attention Deficit-Hyperactivity Disorder in Children with Comorbid Conditions.儿童共病注意缺陷多动障碍的精神药理学治疗。
Pediatr Neurol. 2018 May;82:7-12. doi: 10.1016/j.pediatrneurol.2017.09.010. Epub 2017 Sep 27.
8
Attention Deficit Hyperactivity Disorder in Preschool-Age Children.学龄前儿童注意力缺陷多动障碍
Child Adolesc Psychiatr Clin N Am. 2017 Jul;26(3):523-538. doi: 10.1016/j.chc.2017.02.007.
9
Cardiovascular considerations of attention deficit hyperactivity disorder medications: a report of the European Network on Hyperactivity Disorders work group, European Attention Deficit Hyperactivity Disorder Guidelines Group on attention deficit hyperactivity disorder drug safety meeting.注意缺陷多动障碍药物的心血管方面考量：欧洲多动障碍网络工作组报告，欧洲注意缺陷多动障碍指南组注意缺陷多动障碍药物安全会议
Cardiol Young. 2012 Feb;22(1):63-70. doi: 10.1017/S1047951111000928. Epub 2011 Jul 19.
10
Positive association between attention-deficit/ hyperactivity disorder medication use and academic achievement during elementary school.小学阶段注意力缺陷多动障碍药物使用与学业成绩之间的正相关关系。
Pediatrics. 2009 May;123(5):1273-9. doi: 10.1542/peds.2008-1597.

引用本文的文献

1
Recent Trends in Medication Treatment for Attention-Deficit Hyperactivity Disorder.注意缺陷多动障碍药物治疗的近期趋势
Psychiatr Serv. 2025 May 28:appips20240574. doi: 10.1176/appi.ps.20240574.

本文引用的文献

1
ADHD Pharmacotherapy and Mortality in Individuals With ADHD.注意缺陷多动障碍的药物治疗与患有注意缺陷多动障碍个体的死亡率
JAMA. 2024 Mar 12;331(10):850-860. doi: 10.1001/jama.2024.0851.
2
Trends in Use of Telemedicine for Stimulant Initiation Among Children and Adults.儿童和成人中使用远程医疗启动兴奋剂的趋势。
Psychiatr Serv. 2024 Jul 1;75(7):630-637. doi: 10.1176/appi.ps.20230421. Epub 2024 Jan 19.
3
Trends in Incident Prescriptions for Behavioral Health Medications in the US, 2018-2022.2018-2022 年美国行为健康药物新处方趋势。
JAMA Psychiatry. 2024 Apr 1;81(4):396-405. doi: 10.1001/jamapsychiatry.2023.5045.
4
ADHD medication discontinuation and persistence across the lifespan: a retrospective observational study using population-based databases.ADHD 药物停药和终身维持情况：一项基于人群数据库的回顾性观察研究。
Lancet Psychiatry. 2024 Jan;11(1):16-26. doi: 10.1016/S2215-0366(23)00332-2. Epub 2023 Nov 27.
5
Attention-Deficit/Hyperactivity Disorder Medications and Long-Term Risk of Cardiovascular Diseases.注意缺陷多动障碍药物与长期心血管疾病风险。
JAMA Psychiatry. 2024 Feb 1;81(2):178-187. doi: 10.1001/jamapsychiatry.2023.4294.
6
Sudden Increases in U.S. Stimulant Prescribing: Alarming or Not?美国兴奋剂处方量的突然增加：令人担忧还是并非如此？
J Atten Disord. 2023 Apr;27(6):571-574. doi: 10.1177/10870547231164155. Epub 2023 Mar 22.
7
Functional Impairments Associated With ADHD in Adulthood and the Impact of Pharmacological Treatment.与成年人 ADHD 相关的功能障碍及药物治疗的影响。
J Atten Disord. 2023 May;27(7):669-697. doi: 10.1177/10870547231158572. Epub 2023 Mar 6.
8
Pharmacotherapy for Attention-Deficit/Hyperactivity Disorder and Retention in Outpatient Substance Use Disorder Treatment: A Retrospective Cohort Study.治疗注意缺陷多动障碍和物质使用障碍门诊治疗中保持治疗的药物治疗：一项回顾性队列研究。
J Clin Psychiatry. 2021 Feb 23;82(2):20m13598. doi: 10.4088/JCP.20m13598.
9
Pharmacologic Treatment of Attention Deficit-Hyperactivity Disorder.注意缺陷多动障碍的药物治疗
N Engl J Med. 2020 Sep 10;383(11):1050-1056. doi: 10.1056/NEJMra1917069.
10
Risks and Benefits of Attention-Deficit/Hyperactivity Disorder Medication on Behavioral and Neuropsychiatric Outcomes: A Qualitative Review of Pharmacoepidemiology Studies Using Linked Prescription Databases.注意缺陷多动障碍药物治疗对行为和神经精神结局的风险和益处：使用连锁处方数据库的药物流行病学研究的定性综述。
Biol Psychiatry. 2019 Sep 1;86(5):335-343. doi: 10.1016/j.biopsych.2019.04.009. Epub 2019 Apr 17.

Treating Attention-Deficit/Hyperactivity Disorder Matters.

作者信息

Levin Frances R, Hernandez Mariely, Mariani John J

机构信息

Division on Substance Use Disorders, New York State Psychiatric Institute, New York, New York.

Department of Psychiatry, Columbia University Irving Medical Center, New York, New York.

出版信息

JAMA. 2024 Mar 12;331(10):831-833. doi: 10.1001/jama.2024.1755.

DOI:10.1001/jama.2024.1755
PMID:38470393
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11562873/
Abstract
摘要